A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 06 2021
Historique:
received: 05 03 2021
accepted: 03 06 2021
entrez: 17 6 2021
pubmed: 18 6 2021
medline: 8 7 2021
Statut: epublish

Résumé

Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.

Identifiants

pubmed: 34135391
doi: 10.1038/s41598-021-92070-w
pii: 10.1038/s41598-021-92070-w
pmc: PMC8209156
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12676

Références

Emerg Infect Dis. 2020 Nov;26(11):2770-2771
pubmed: 32917294
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Ann Intern Med. 2021 Apr;174(4):501-510
pubmed: 33428446
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
Int J Infect Dis. 2020 Jul;96:288-290
pubmed: 32437933
J Clin Virol. 2020 Sep;130:104567
pubmed: 32750665

Auteurs

Nikki Carter (N)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Maryam Clausen (M)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Rebecca A Halpin (RA)

Early Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.

Colin Blackmore (C)

R&D IT, AstraZeneca, Cambridge, UK.

Kang Cai (K)

Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Oona Delpuech (O)

Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.

Alexander Kohlmann (A)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.

Otto Magnusson (O)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Ruth March (R)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.

Daniel O'Neill (D)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Kasthuri Prakash (K)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

James Sherwood (J)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.

Tabetha Sundin (T)

Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA.

Jason Swift (J)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.

Azar Tarakameh (A)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Marilou Wijdicks (M)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.

Daniel Wise (D)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Mark Fidock (M)

Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK. mark.fidock@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH